- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04692792
Efficacy Evaluation of Dai Dai Flower on Body Weight
3. august 2021 opdateret af: TCI Co., Ltd.
To assess the Dai Dai flower extract on body weight control
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
50
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Taichung, Taiwan, 404
- China Medical University
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
20 år til 65 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Healthy male or female aged between 20 and 60 years old
- Body mass index (BMI) ≥ 24 (kg/m^2) or body fat mass ≥ 25%
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Implementation in weight loss programs, consumption drugs or supplements for weight control before 3 months of this study
- Participate weight control or fat loss human studies before 3 months of this study
- History of cardiovascular disease, liver disease, kidney disease, endocrine disease, or other major organic diseases (according to subjects reporting).
- Person who has received major surgery or bariatric surgery (according to medical history).
- Person who has received constant drug use.
- People with mental illness
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo drink
|
consume 1 bottle (50 mL) per day for 8 weeks
|
|
Eksperimentel: Dai Dai flower drink
|
consume 1 bottle (50 mL) per day for 8 weeks
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The change of body weight
Tidsramme: Change from Baseline body weight at 8 weeks
|
The body weight (kg) was assessed by InBody.
|
Change from Baseline body weight at 8 weeks
|
|
The change of BMI
Tidsramme: Change from Baseline BMI at 8 weeks
|
The BMI was assessed by InBody.
|
Change from Baseline BMI at 8 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The change of body fat mass
Tidsramme: Change from Baseline body fat mass at 8 weeks
|
The body fat mass (kg) was assessed by InBody.
|
Change from Baseline body fat mass at 8 weeks
|
|
The change of visceral fat mass
Tidsramme: Change from Baseline visceral fat mass at 8 weeks
|
The visceral fat mass (kg) was assessed by InBody.
|
Change from Baseline visceral fat mass at 8 weeks
|
|
The change of waist-hip ratio
Tidsramme: Change from Baseline waist-hip ratio at 8 weeks
|
The waist-hip ratio was assessed by measuring tape.
|
Change from Baseline waist-hip ratio at 8 weeks
|
|
The change of basal metabolic rate
Tidsramme: Change from Baseline basal metabolic rate at 8 weeks
|
The basal metabolic rate was assessed by InBody.
|
Change from Baseline basal metabolic rate at 8 weeks
|
|
The change of AST
Tidsramme: Change from Baseline AST at 8 weeks
|
Venous blood was sampled to measure concentrations of aspartate transaminase (AST)
|
Change from Baseline AST at 8 weeks
|
|
The change of ALT
Tidsramme: Change from Baseline ALT at 8 weeks
|
Venous blood was sampled to measure concentrations of alanine aminotransferase (ALT)
|
Change from Baseline ALT at 8 weeks
|
|
The change of Creatinine
Tidsramme: Change from Baseline creatinine at 8 weeks
|
Venous blood was sampled to measure concentrations of creatinine
|
Change from Baseline creatinine at 8 weeks
|
|
The change of BUN
Tidsramme: Change from Baseline BUN at 8 weeks
|
Venous blood was sampled to measure concentrations of blood urea nitrogen (BUN)
|
Change from Baseline BUN at 8 weeks
|
|
The change of fasting glycemia
Tidsramme: Change from Baseline fasting glycemia at 8 weeks
|
Venous blood was sampled to measure concentrations of fasting glycemia
|
Change from Baseline fasting glycemia at 8 weeks
|
|
The change of total cholesterol
Tidsramme: Change from Baseline total cholesterol at 8 weeks
|
Venous blood was sampled to measure concentrations of total cholesterol
|
Change from Baseline total cholesterol at 8 weeks
|
|
The change of triglyceride
Tidsramme: Change from Baseline triglyceride at 8 weeks
|
Venous blood was sampled to measure concentrations of triglyceride
|
Change from Baseline triglyceride at 8 weeks
|
|
The change of HDL-cholesterol
Tidsramme: Change from Baseline HDL-cholesterol at 8 weeks
|
Venous blood was sampled to measure concentrations of HDL-cholesterol
|
Change from Baseline HDL-cholesterol at 8 weeks
|
|
The change of LDL-cholesterol
Tidsramme: Change from Baseline LDL-cholesterol at 8 weeks
|
Venous blood was sampled to measure concentrations of LDL-cholesterol
|
Change from Baseline LDL-cholesterol at 8 weeks
|
|
The change of insulin
Tidsramme: Change from Baseline insulin at 8 weeks
|
Venous blood was sampled to measure concentrations of insulin
|
Change from Baseline insulin at 8 weeks
|
|
The change of adiponectin
Tidsramme: Change from Baseline adiponectin at 8 weeks
|
Venous blood was sampled to measure concentrations of adiponectin
|
Change from Baseline adiponectin at 8 weeks
|
|
The change of leptin
Tidsramme: Change from Baseline leptin at 8 weeks
|
Venous blood was sampled to measure concentrations of leptin
|
Change from Baseline leptin at 8 weeks
|
|
The change of IFN-γ
Tidsramme: Change from Baseline IFN-γ at 8 weeks
|
Venous blood was sampled to measure concentrations of IFN-γ
|
Change from Baseline IFN-γ at 8 weeks
|
|
The change of IL-2
Tidsramme: Change from Baseline IL-2 at 8 weeks
|
Venous blood was sampled to measure concentrations of IL-2
|
Change from Baseline IL-2 at 8 weeks
|
|
The change of IL-1beta
Tidsramme: Change from Baseline IL-1beta at 8 weeks
|
Venous blood was sampled to measure concentrations of IL-1beta
|
Change from Baseline IL-1beta at 8 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
4. januar 2021
Primær færdiggørelse (Faktiske)
6. marts 2021
Studieafslutning (Faktiske)
15. juni 2021
Datoer for studieregistrering
Først indsendt
29. december 2020
Først indsendt, der opfyldte QC-kriterier
29. december 2020
Først opslået (Faktiske)
5. januar 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
4. august 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
3. august 2021
Sidst verificeret
1. august 2021
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CMUH109-REC1-161
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Placebo drink
-
Virginia Polytechnic Institute and State UniversityAfsluttet
-
TCI Co., Ltd.RekrutteringAngst depression | Søvnforstyrrelse (forstyrrelse)Taiwan
-
TCI Co., Ltd.Afsluttet
-
TCI Co., Ltd.Afsluttet
-
Wageningen UniversityMaastricht University Medical Center; Top Institute Food and NutritionAfsluttet
-
University of AarhusAfsluttetDiabetes mellitus, type 2 | Hjertesvigt med bevaret ejektionsfraktion | KetonæmiDanmark